Iovance Biotherapeutics, Inc. (IOVA): Price and Financial Metrics
IOVA Price/Volume Stats
| Current price | $11.31 | 52-week high | $18.33 |
| Prev. close | $11.72 | 52-week low | $3.21 |
| Day low | $11.01 | Volume | 5,264,000 |
| Day high | $11.69 | Avg. volume | 8,764,211 |
| 50-day MA | $13.76 | Dividend yield | N/A |
| 200-day MA | $8.14 | Market Cap | 3.16B |
IOVA Stock Price Chart Interactive Chart >
Iovance Biotherapeutics, Inc. (IOVA) Company Bio
Iovance Biotherapeutics, formerly known as Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company was founded in 2007 and is based in Woodland Hills, California.
Latest IOVA News From Around the Web
Below are the latest news stories about IOVANCE BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate IOVA as an investment opportunity.
Why Iovance Biotherapeutics Stock Popped TodayIovance rebounded nicely after yesterday's drop, which came after the FDA put a clinical hold on its cancer-therapy trial. |
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
3 Charts For Investors to Watch Thursday: GC Education, Iovance, EthereumThese two stocks and one cryptocurrency are worth watching today. We discuss why and identify important chart levels to watch. |
Gold nears $2100, biotech stocks on the move: Trending tickersGold (GC=F) prices are inching closer to $2,100 per ounce. It's an area that has been a bit of a resistance level for the precious metal. In the world of biotech, Cytokinetics (CYTK) shares soared more than 80% after a trial for its hear drug showed promising results. Meanwhile, Iovance Biotherapeutics (IOVA) shares fell 18% after the Food and Drug Administration paused clinical trials of a lung cancer treatment following the death of a patient. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient DeathWednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen. During the clinical hold, Iovance will pause enrollment and the LN-145 TIL treatment regimen for new patients in IO |
IOVA Price Returns
| 1-mo | -26.37% |
| 3-mo | 45.37% |
| 6-mo | 227.83% |
| 1-year | 98.07% |
| 3-year | -63.63% |
| 5-year | 2.35% |
| YTD | 39.11% |
| 2023 | 27.23% |
| 2022 | -66.53% |
| 2021 | -58.86% |
| 2020 | 67.63% |
| 2019 | 212.77% |
Loading social stream, please wait...